Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|September 30, 2013

DSM Pharmaceuticals Appoints New CEO

DSM Pharmaceutical Products appoints a new CEO and President.

DSM Pharmaceutical

Products, the contract manufacturing organization of Royal DSM, appointed Lukas Utiger, PhD as its new CEO and President, effective Oct. 1, 2013.

Headquartered in Parsippany, NJ, the DSM Pharmaceutical Products business group includes DSM Biologics/BioSolutions, DSM Pharma Chemicals, DSM Exclusive Synthesis & Intermediates, and DSM Pharmaceuticals with operations in the US, Europe, and Australia.

Utiger has 25 years of industry experience, managing both small- and large-molecule manufacturing, as well as research and development.

Prior to joining DSM, Utiger was responsible for Lonza’s Bioscience division, where for more than 10 years he also served on the executive committee for various divisions including the pharma contract manufacturing organization and nutrition.

Source:

DSM Pharmaceutical


Related to this article

The BioPharm Brief: Cosentyx Approved in Polymyalgia Rheumatica, a Phase 3 Survival Win for an AML Vaccine, and $173 Million for In Vivo Bone Marrow Editing
FDA approves Novartis’ Cosentyx as the first anti-IL-17 biologic for polymyalgia rheumatica, SELLAS Life Sciences’ WT1-targeted peptide vaccine galinpepimut-S meets its overall survival primary endpoint in the phase 3 REGAL trial in AML, and Marrow Therapeutics launches with $173 million to develop bone marrow-targeted genetic medicines.